company background image
VCNX

Vaccinex NasdaqCM:VCNX Stock Report

Last Price

US$1.10

Market Cap

US$46.9m

7D

6.8%

1Y

-53.2%

Updated

13 Aug, 2022

Data

Company Financials
VCNX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

VCNX Stock Overview

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs.

Vaccinex, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vaccinex
Historical stock prices
Current Share PriceUS$1.10
52 Week HighUS$2.53
52 Week LowUS$0.90
Beta0.99
1 Month Change-5.98%
3 Month Change-7.56%
1 Year Change-53.19%
3 Year Change-77.96%
5 Year Changen/a
Change since IPO-90.33%

Recent News & Updates

Shareholder Returns

VCNXUS BiotechsUS Market
7D6.8%1.2%3.2%
1Y-53.2%-21.7%-10.2%

Return vs Industry: VCNX underperformed the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: VCNX underperformed the US Market which returned -10.1% over the past year.

Price Volatility

Is VCNX's price volatile compared to industry and market?
VCNX volatility
VCNX Average Weekly Movement9.2%
Biotechs Industry Average Movement12.5%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: VCNX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: VCNX's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200140Maurice Zaudererhttps://www.vaccinex.com

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington’s disease, Alzheimer’s disease, osteosarcoma, and melanoma.

Vaccinex, Inc. Fundamentals Summary

How do Vaccinex's earnings and revenue compare to its market cap?
VCNX fundamental statistics
Market CapUS$46.93m
Earnings (TTM)-US$20.40m
Revenue (TTM)US$50.00k

940.2x

P/S Ratio

-2.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VCNX income statement (TTM)
RevenueUS$50.00k
Cost of RevenueUS$14.61m
Gross Profit-US$14.56m
Other ExpensesUS$5.84m
Earnings-US$20.40m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.48
Gross Margin-29,126.00%
Net Profit Margin-40,802.00%
Debt/Equity Ratio1.4%

How did VCNX perform over the long term?

See historical performance and comparison